9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
Star0
Identification
- Generic Name
- 9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
- DrugBank Accession Number
- DB02842
- Background
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 322.4042
Monoisotopic: 322.179361346 - Chemical Formula
- C19H22N4O
- Synonyms
- 9-amino-N-(3-dimethylaminopropyl)acridine-4-carboxamide
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UDNA intercalationHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Benzoquinolines
- Direct Parent
- Acridines
- Alternative Parents
- Quinoline carboxamides / 4-aminoquinolines / Aminopyridines and derivatives / Benzenoids / Heteroaromatic compounds / Trialkylamines / Secondary carboxylic acid amides / Amino acids and derivatives / Azacyclic compounds / Primary amines show 4 more
- Substituents
- 4-aminoquinoline / Acridine / Amine / Amino acid or derivatives / Aminopyridine / Aminoquinoline / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carboxamide group show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0LY4HYL6F8
- CAS number
- Not Available
- InChI Key
- VNWAULKXOPRJEL-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H22N4O/c1-23(2)12-6-11-21-19(24)15-9-5-8-14-17(20)13-7-3-4-10-16(13)22-18(14)15/h3-5,7-10H,6,11-12H2,1-2H3,(H2,20,22)(H,21,24)
- IUPAC Name
- 9-amino-N-[3-(dimethylamino)propyl]acridine-4-carboxamide
- SMILES
- CN(C)CCCNC(=O)C1=CC=CC2=C(N)C3=C(C=CC=C3)N=C12
References
- General References
- Not Available
- External Links
- PubChem Compound
- 150238
- PubChem Substance
- 46505229
- ChemSpider
- 132441
- BindingDB
- 50004358
- ChEMBL
- CHEMBL287038
- ZINC
- ZINC000005957683
- PDBe Ligand
- 7AD
- PDB Entries
- 1rqy
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0776 mg/mL ALOGPS logP 2.37 ALOGPS logP 1.83 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 14.74 Chemaxon pKa (Strongest Basic) 9.33 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 71.25 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 97.62 m3·mol-1 Chemaxon Polarizability 37.12 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9876 Blood Brain Barrier + 0.9152 Caco-2 permeable + 0.5 P-glycoprotein substrate Substrate 0.7298 P-glycoprotein inhibitor I Non-inhibitor 0.7549 P-glycoprotein inhibitor II Non-inhibitor 0.5971 Renal organic cation transporter Non-inhibitor 0.5216 CYP450 2C9 substrate Non-substrate 0.861 CYP450 2D6 substrate Non-substrate 0.5248 CYP450 3A4 substrate Substrate 0.6456 CYP450 1A2 substrate Inhibitor 0.7153 CYP450 2C9 inhibitor Non-inhibitor 0.9086 CYP450 2D6 inhibitor Non-inhibitor 0.5997 CYP450 2C19 inhibitor Non-inhibitor 0.8901 CYP450 3A4 inhibitor Non-inhibitor 0.6871 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.909 Ames test AMES toxic 0.5819 Carcinogenicity Non-carcinogens 0.8817 Biodegradation Not ready biodegradable 0.9916 Rat acute toxicity 2.5730 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9765 hERG inhibition (predictor II) Inhibitor 0.8477
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-0059000000-40836a966f61e47ad541 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-1009000000-7034bb775137f723d4dd Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-0091000000-c31bef107562f69385e7 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00dj-7269000000-567970c6b8e9cd646284 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00dj-5390000000-f53f0070681505174e4f Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-7970000000-e88c13f76dea4ce8a02b Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 185.9237789 predictedDarkChem Lite v0.1.0 [M-H]- 178.25302 predictedDeepCCS 1.0 (2019) [M+H]+ 186.3477789 predictedDarkChem Lite v0.1.0 [M+H]+ 180.61102 predictedDeepCCS 1.0 (2019) [M+Na]+ 185.9111789 predictedDarkChem Lite v0.1.0 [M+Na]+ 186.9772 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsDNA
Unknown
Intercalation
References
- Adams A, Guss JM, Denny WA, Wakelin LP: Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons. Nucleic Acids Res. 2002 Feb 1;30(3):719-25. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52